Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05207761
- Locations
- 🇰🇷
Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of
Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 206
- Registration Number
- NCT05193565
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul, St.Mary's Hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-828, D097, D337
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 63
- Registration Number
- NCT05192356
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects
Phase 1
Completed
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: D418 Tab.Drug: CKD-388 Tab.
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 65
- Registration Number
- NCT05189288
- Locations
- 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 33
- Registration Number
- NCT05113693
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects
Phase 1
- Conditions
- GERD
- Interventions
- Drug: CKD-382, D860, D027
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 42
- Registration Number
- NCT05108038
- Locations
- 🇰🇷
Chungbuk Ntional University Hospital, Cheongju-si, Korea, Republic of
Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 71
- Registration Number
- NCT05089279
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients
Phase 4
Not yet recruiting
- Conditions
- Vascular Cognitive Impairment
- Interventions
- Drug: Placebo of Choline Alfoscerate 400mg
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 418
- Registration Number
- NCT05050604
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus
Completed
- Conditions
- Type2 Diabetes
- Interventions
- Drug: Duvie(Lobeglitazone) tab 0.5mg
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 2228
- Registration Number
- NCT05043467
- Locations
- 🇰🇷
Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
Phase 4
Not yet recruiting
- Conditions
- Mild Cognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 418
- Registration Number
- NCT05041790
- Locations
- 🇰🇷
Asan Medical Center Institutional Review Board, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath